0001567619-22-015554.txt : 20220811
0001567619-22-015554.hdr.sgml : 20220811
20220811141736
ACCESSION NUMBER: 0001567619-22-015554
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20220811
DATE AS OF CHANGE: 20220811
EFFECTIVENESS DATE: 20220811
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centrexion Therapeutics Corp
CENTRAL INDEX KEY: 0001592052
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320402377
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-448502
FILM NUMBER: 221155038
BUSINESS ADDRESS:
STREET 1: 200 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: (617) 837-6911
MAIL ADDRESS:
STREET 1: 200 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: Centrexion Corp
DATE OF NAME CHANGE: 20131114
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001592052
Centrexion Therapeutics Corp
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
617-837-6911
DELAWARE
None
Centrexion Corp
Corporation
true
Jeffrey
B.
Kindler
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Executive Officer
Director
James
N.
Campbell, M.D.
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Executive Officer
Director
Randall
M.
Stevens
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Executive Officer
Michael
J.
Ward
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Executive Officer
Sol
Barer
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
Colin
Hill
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
Dezhi
Kang, Ph.D.
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
J.
C.
Lopez, M.D.
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
Joseph
R.
Swedish
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
Shawn
Tomasello
200 STATE STREET, 6TH FLOOR
BOSTON
MA
MASSACHUSETTS
02109
Director
Peter
Wirth
200 STATE STREET, 6TH FLOOR
Boston
MA
MASSACHUSETTS
02109
Director
Biotechnology
Decline to Disclose
- 06b
true
0001567619-22-013424
2022-05-24
false
true
true
true
false
0
Maxim Group LLC
120708
None
None
300 Park Avenue
16th Floor
New York
NY
NEW YORK
10022
All States
false
29140000
29140000
0
false
47
0
2622600
true
The compensation payable to the finder (Maxim Group LLC) consisted of (i) a cash fee (listed above) plus (ii) the issuance of approximately 475,954 shares of common stock and warrants to purchase up to 1,748,400 shares common stock.
0
false
Centrexion Therapeutics Corp
/s/ Michael Ward
Michael Ward
Chief Financial Officer, Treasurer, and Secretary
2022-08-10